Skip to main content Skip to navigation
PE Mouse Anti-Mouse CD22.2
Product Details
Down Arrow Up Arrow


BD Pharmingen™
Lyb8.2; Lyb-8.2; BL-CAM; Siglec-2
Mouse (QC Testing)
Mouse DBA/1 IgG1, κ
B10.D2 mouse splenocytes
Flow cytometry (Routinely Tested)
0.2 mg/ml
12483
AB_2295739
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with R-PE under optimum conditions, and unconjugated antibody and free PE were removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
553384 Rev. 10
Antibody Details
Down Arrow Up Arrow
Cy34.1

The Cy34.1 monoclonal antibody specifically binds to the B-lymphocyte differentiation antigen CD22 on strains having the Lyb-8.2 alloantigen (e.g., A, BALB/c, CBA, C3H/He, C57BL, C57L, C58, SJL, SWR, but not AKR, DBA/1, DBA/2, NZB, PL). CD22 is expressed at high levels on mature peripheral B lymphocytes (follicular  and marginal zone), B-1 cells (CD5+ B cells), and plasma cells.  It is a member of the Ig gene superfamily and associates with the B-cell antigen receptor. Its sialic acid- binding immunoglobulin-like lectin (siglec) extracellular region mediates B-cell adhesion to ligands on endothelial cells in the bone marrow.  Its intracellular  domain is phosphorylated after cross-linking of antigen receptor  or MHC class II antigen.  It is involved in negative regulation of B-cell activation and protection from autoimmunity.  B-cell proliferative responses to LPS or anti-mouse Ig µ chain are augmented in the presence of Cy34.1 mAb.

This antibody is routinely tested by flow cytometric analysis.  Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

553384 Rev. 10
Format Details
Down Arrow Up Arrow
PE
R-Phycoerythrin (PE), is part of the BD family of Phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 496 nm and 566 nm and an emission maximum (Em Max) at 576 nm. PE is designed to be excited by the Blue (488 nm), Green (532 nm) and Yellow-Green (561 nm) lasers and detected using an optical filter centered near 575 nm (e.g., a 575/26-nm bandpass filter). As PE is excited by multiple lasers, this can result in cross-laser excitation and fluorescence spillover on instruments with various combinations of Blue, Green, and Yellow-Green lasers. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
PE
Yellow-Green 488 nm, 532 nm, 561 nm
496 nm, 566 nm
576 nm
553384 Rev.10
Citations & References
Down Arrow Up Arrow

Development References (11)

  1. Bobbitt KR, Justement LB. Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22. J Immunol. 2000; 165(10):5588-5596. (Biology). View Reference
  2. Doody GM, Justement LB, Delibrias CC. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995; 269(5221):242-244. (Biology). View Reference
  3. Erickson LD, Tygrett LT, Bhatia SK, Grabstein KH, Waldschmidt TJ. Differential expression of CD22 (Lyb8) on murine B cells. Int Immunol. 1996; 8(7):1121-1129. (Biology). View Reference
  4. Law CL, Sidorenko SP, Clark EA. Regulation of lymphocyte activation by the cell-surface molecule CD22. Immunol Today. 1994; 15(9):442-449. (Biology). View Reference
  5. Law CL, Torres RM, Sundberg HA. Organization of the murine Cd22 locus. Mapping to chromosome 7 and characterization of two alleles. J Immunol. 1993; 151(1):175-187. (Clone-specific). View Reference
  6. Mary C, Laporte C, Parzy D. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol. 2000; 165(6):2987-2996. (Biology). View Reference
  7. Nitschke L, Floyd H, Ferguson DJ, Crocker PR. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med. 1999; 189(9):1513-1518. (Biology). View Reference
  8. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science. 1996; 274(5288):798-801. (Biology). View Reference
  9. Stall AM, Wells SM. FACS analysis of murine B-cell populations. In: Herzenberg LA, Weir DM, Blackwell C, ed. Weir's Handbook of Experimental Immunology. Blackwell Science Publishers; 1997:63.1-63.17.
  10. Stoddart A, Ray RJ, Paige CJ. Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM. Int Immunol. 1997; 9(10):1571-1579. (Biology). View Reference
  11. Symington FW, Subbarao B, Mosier DE, Sprent J. Lyb-8.2: A new B cell antigen defined and characterized with a monoclonal antibody. Immunogenetics. 1982; 16(5):381-391. (Immunogen). View Reference
View All (11) View Less
553384 Rev. 10

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.